

Science can...

AstraZeneca Pharma India Limited
Annual Report 2022-2023



Science Can...



As the world undergoes constant evolution, AstraZeneca Pharma India Limited (AstraZeneca) is constantly redefining the standard of care by offering life-enhancing and life-saving treatments. We are committed to transforming outcomes for our patients, increasing access to healthcare and making healthcare systems more resilient, while growing the success of our Company.

Pushing the boundaries of science, the Company is continuously transforming healthcare with its unwavering dedication to scientific excellence.

AstraZeneca's success stems from its focus on research and development, investing significantly to drive groundbreaking discoveries and reimagine the future of medicine.

As a leading pharmaceutical company, AstraZeneca is leveraging its scientific expertise to provide accessible and effective treatment for patients globally. Collaborating with experts worldwide, the Company tackles the most pressing medical challenges across diverse therapeutic areas. In oncology, the Company has made remarkable strides, developing innovative treatments that target the underlying mechanisms of cancer.

As the burden of disease grows and the population ages, we believe that science is key to helping unlock the answers to healthcare challenges. With a relentless pursuit of innovative solutions and dedication to improving global health, AstraZeneca shapes the future of medicine, forging a path toward a healthier and brighter world for all.

AstraZeneca's spirit of bringing science-led innovations for one and all extends beyond medicine as it actively engages in sustainability and ethical practices. By aligning its operations with social responsibility, the Company ensures its scientific advancements create a sustainable and equitable future.



Contents

Managing Director's Statement 2

Harnessing Science to Create Novel Therapies 4

Science and Innovation 6

Growth and Therapy Area Leadership 8

People and Sustainability 12

Notice 20

Board's Report 30

Management Discussion and Analysis Report 48

Report on Corporate Governance 53

Business Responsibility and Sustainability Report 69

Independent Auditor's Report 96

Balance Sheet 104

Statement of Profit and Loss 105

Statement of Changes in Equity 106

Statement of Cash Flows 107

Notes to the Financial Statements 109

10-Year Summary Statements 151

Managing Director’s Statement



Dr. Sanjeev Panchal
Managing Director

At AstraZeneca, we are transforming the future of healthcare by unlocking the power of what science can do.

Dear Shareholders,

The reopening of world economies following the pandemic has presented AstraZeneca with a unique opportunity to shape the future of the healthcare industry. Through our cutting-edge scientific advancements, we are revolutionising patient outcomes and solidifying our position as a leader in the field. Our organisation wholeheartedly embraces the mindset of ‘Science Can, We Can’, and it is driven by our shared values of serving people, society and the planet.

I would like to express my sincere gratitude to you for your trust in us as an organisation that is genuinely committed to unlocking the potential of scientific research in order to develop exceptional medicines for patients, with the ultimate goal of treating and eventually curing diseases.

It brings me great pleasure to establish this connection with you and provide an update on the advancements and achievements of AstraZeneca over the past year. We envision a future of healthcare that is the immense potential of scientific breakthroughs. As the newly appointed Managing Director, I feel privileged to lead our organisation in harnessing the power of science to deliver world-class medicines and transform patient outcomes.

Financial Performance

In FY 2022-23, we demonstrated robust performance and successfully executed our long-term growth strategy. We achieved a significant milestone, with our total income amounting to ₹ 10,291 million, indicating a remarkable growth rate of 25%. This notable growth was driven by the sale of pharmaceutical products, which witnessed a substantial increase of 24%, reaching ₹ 9,417 million.

Within our therapy areas, we experienced exceptional growth. Oncology revenue surged by 48%, demonstrating our dedication to addressing critical healthcare needs in the field of cancer. The Respiratory and Immunology segment exhibited impressive growth of 52%, underscoring our commitment to improving respiratory health and immune disorders.

Furthermore, our Cardiovascular portfolio commendably grew 18%. However, we did encounter a decline of 23% in the Diabetes segment.

These outstanding results reflect the unwavering trust bestowed upon us by the Indian healthcare ecosystem, further affirming our commitment to enhancing patient outcomes.

The Power of Science

As a science-led biopharmaceutical Company, AstraZeneca is highly regarded and trusted by our stakeholders for our unwavering dedication to pushing the boundaries of scientific innovation. In FY 2022-23, we achieved significant milestones in terms of regulatory approvals, submissions, and pipeline progression

events. At the core of our mission is a steadfast commitment to improving health outcomes. We have developed an access to healthcare strategy that encompasses several pillars. We strive to make our medicines widely available and affordable, ensuring that patients can benefit from the latest advancements in medical science. Additionally, we actively support the development of sustainable health systems and infrastructure, recognising the importance of a robust healthcare ecosystem in delivering quality care to individuals and communities. Moreover, we are committed to raising disease awareness and promoting preventive measures, empowering individuals to take control of their health and well-being.

Therapy Area Progress

Throughout the year, the impact of our pioneering science has been evident across all therapy areas. We have obtained significant regulatory approvals that have enabled us to serve patients who would otherwise face limited or no treatment options. Following the global acquisition of Alexion in 2021, we have expanded our portfolio to bring innovative therapies for rare diseases to the Indian market. As a result of this strategic acquisition, India stands among the first few countries in Asia to offer rare disease therapies from the esteemed Alexion portfolio. One such groundbreaking therapy is Selumetinib, which aims to address the unmet medical needs of patients with rare disease NF1, eventually improving their quality of life. This expansion of our portfolio reflects our unwavering commitment to bringing transformative medicines to patients, particularly those with limited treatment options. Additionally, we are dedicated to emphasising the importance of early diagnosis and holistic care. With this, we strive to enhance patient outcomes and ensure that individuals receive the utmost care throughout their healthcare journey.

Addressing Healthcare Challenges with Advanced Technology

We understand the significance of early diagnosis in facilitating precise treatment. To transform this vision into reality, we have dedicated considerable time and effort in partnerships and initiatives. One of our key endeavors is the A.Catalyst Network’s India Health Innovation Hub, which operates in collaboration with the Indo-Sweden Healthcare Innovation Centre (ISHIC). Together, we are diligently working towards making healthcare affordable and accessible to everyone. Notably, our projects such as HeartBeat, SEARCH, SAHAYOG, and several others play a crucial role in disseminating accurate awareness pertaining to various disease areas. Furthermore, these initiatives actively contribute to early detection, ultimately leading to better health outcomes for individuals.

A Great Place to Work

Innovation flourishes within a diverse workplace that fosters a sense of safety and empowerment and encourages collaboration while challenging conventional thinking. The innovative breakthroughs we have achieved in the past year can be attributed to our exceptional and collaborative workforce. I extend my gratitude to all my colleagues at AstraZeneca for their unwavering dedication and commitment in delivering outstanding performance and ensuring that our medicines reach patients across the country. Our steadfast commitment lies in nurturing inclusivity and diversity, creating an environment where individuals can unleash their potential and continuously grow and evolve.

Commitment to Society and the Planet

Driven by our core value of ‘Doing the right thing’, we are dedicated to making meaningful contributions to society and the planet. We recognise the interdependence

of a healthy planet and healthy people and are taking bold actions to expand healthcare access while reducing our impact on the climate.

One of our impactful initiatives is the Ganga Godavari Screening Program, which continues to identify cancer incidence in women through preventative screening camps. It has benefited over 8,500 women in underserved communities over the past few years. In addition, the Young Health Program focuses on empowering young people to make informed health choices through health information centers in New Delhi and Karnataka, we have reached over 500,000 individuals, equipping them with valuable knowledge for a healthier future.

Furthermore, we have implemented Ambition Zero Carbon strategy, demonstrating our commitment to combating climate change. As part of our global AZ Forest Program, we have planted over 10.5 million trees worldwide since 2020, including dedicated efforts in India. We actively engage with the local community to ensure the sustainability of the sites where we initiated the plantation, fostering long-term environmental stewardship.

Looking Ahead

These are undeniably exhilarating times as we make remarkable progress in our community programs and persistently tackle healthcare challenges. We are dedicated to taking every possible measure to build a better future for healthcare. I am confident that we will demonstrate the transformational power of science.

As we consistently push the boundaries of science, we remain steadfast in upholding our values in all our interactions and taking decisive action.

Dr. Sanjeev Panchal
Managing Director

Harnessing Science to Create Novel Therapies

By leveraging the power of science and pioneering innovation, AstraZeneca is committed to developing transformative medications that have a profound impact on the lives of patients. As a leading global pharmaceutical company, AstraZeneca consistently delivers exceptional solutions and interventions while upholding a strong culture rooted in core values. The Company has earned widespread recognition as an outstanding workplace, driven by its unwavering dedication to sustainability, inclusivity, and diversity. Moreover, AstraZeneca's relentless passion for fostering a culture of continuous learning reinforces its steadfast commitment to achieving excellence.

AstraZeneca's Values



We follow science



We play to win



We are entrepreneurial



We do the right thing



We put patients first

Strategic Priorities

Guided by the Company's unwavering dedication and fueled by its passion, AstraZeneca is resolutely working towards achieving its purpose and making a lasting impact in the lives of patients worldwide.

-  **Science and Innovation**
-  **Growth and Therapy Area Leadership**
-  **People and Sustainability**

Key Therapeutic Areas

AstraZeneca India is dedicated to leading in therapy areas where we believe we can make the most meaningful difference to patients.



1
Cardiovascular, Renal, and Metabolic (CVRM) Diseases



2
Oncology



3
Respiratory and Immunology

1 Cardiovascular, Renal, and Metabolic (CVRM) Diseases

AstraZeneca, a global leader in the fight against cardiovascular, renal, and metabolic (CVRM) diseases, demonstrates its unparalleled proficiency by addressing intricate medical conditions through patient-centric approaches. The Company's dedicated and interdisciplinary team strives to develop personalised and ground-breaking pharmaceuticals for a wide range of CVRM diseases. As the prevalence of obesity increases and populations continue to age, the risks associated with CVRM escalate.

The Company prioritises enhancing access to medication, advancing its research and development pipeline, and spearheading healthcare innovation to revolutionise the care provided to individuals with CVRM diseases. With its scientific expertise in patient outcomes, AstraZeneca aims to prevent and ultimately cure CVRM diseases.

2 Oncology

With a steadfast emphasis on early detection and intervention, AstraZeneca is actively working towards bringing patients closer to achieving a cure. By leveraging the potential of innovative medicines and novel combinations, the Company is wholly committed to combating metastatic or resistant forms of cancer and attaining significant treatment responses. Through groundbreaking research endeavors, AstraZeneca continuously identifies new biomarkers and therapeutic targets, thereby revolutionising both the diagnosis and treatment strategies employed in the fight against cancer.

Within its Oncology Business Unit, AstraZeneca acknowledges and considers the distinctive characteristics of each tumour, surpassing the constraints associated with the tumour-type classification. Propelled by an ambitious vision of delivering curative solutions for cancer across all stages, the Company diligently follows scientific advancements to unravel the intricate complexities of the disease.

3 Respiratory and Immunology

AstraZeneca is widely recognised as a leading authority in respiratory care, offering a comprehensive portfolio of inhaled and biologic medicines. Our paramount goal is to revolutionise the treatment landscape for asthma and chronic obstructive pulmonary disease (COPD). Our ambition is to transform Respiratory and Immunology care, moving beyond symptom control to disease modification, remission and, one day, cure. The Company is committed to transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases, with a portfolio of inhaled and biologic medicines and a pipeline for the future, seeking to address the challenges and vast unmet medical needs of patients.

By acknowledging the shared pathways and underlying factors between respiratory and immunological disorders, we seamlessly integrates these two fields. The Company meticulously follows the scientific evidence trail from chronic lung diseases to conditions driven by immune dysregulation. Within its Respiratory and Immunology Unit, a dedicated team relentlessly pursues disease control and clinical remission in targeted immune-driven disorders.

Product Portfolio



Science and Innovation

The enduring success of AstraZeneca is fueled by the immense power of science, enabling the Company to transform the future of healthcare. AstraZeneca is actively involved in creating the next generation of therapeutics, utilising diverse drug modalities such as advanced biologics, nucleotide-based treatments, and cell therapies.

The Approach

The Company is dedicated to harnessing the power of science and innovation in ways that have a positive impact on patients, healthcare systems, and the environment. AstraZeneca remains at the forefront of pipeline advancements and leads in the convergence of science, data, and technology. The vision of AstraZeneca revolves around delivering healthcare experiences and outcomes that are of utmost importance to patients, enabling them to lead fulfilling lives. Every decision made across the patient experience is informed by valuable insights from patients themselves, ensuring that their needs are prioritised.

In India, AstraZeneca's clinical trial current pipeline encompasses 64 global clinical studies covering multiple therapeutic areas. In 2022, the Company received three regulatory approvals, enabling the introduction of new medicines to Indian patients. These endeavors expand access to innovative treatments and contribute to improving healthcare outcomes for patients in the country.

Paving the Way for Research and Development

Empowered by advancements in digital technology, data analysis, and artificial intelligence, AstraZeneca is witnessing the accelerated progress of scientific knowledge in understanding diseases, predicting treatment outcomes, delivering transformative medicines, and enhancing patient engagement within and beyond clinical settings. Recognising that achieving these goals requires collaborative efforts, the Company actively collaborates with external partners across academia, biotech, and industry in India. This collaborative approach allows them to tap into the best talent and expertise to tackle complex healthcare challenges.

Shaping a Healthier India through Collaboration and Innovation

Established in 2019 through a tri-partite collaboration between the Swedish Trade Commissioner's office, AIIMS New Delhi, AIIMS Jodhpur, AstraZeneca, and the National Association of Software and Services Companies (NASSCOM) CoE IoT, the A.Catalyst Network's India Health Innovation Hub has a significant role in shaping a healthier India, both in the present and the future. This collaboration was facilitated in partnership with the India-Sweden Healthcare Innovation Centre (ISHIC).

With a vision to make healthcare affordable and accessible to all, the A.Catalyst Network's India Health Innovation Hub strives to foster a collaborative ecosystem of open innovation. Its primary mission is to support startups in addressing healthcare challenges across the country, ultimately improving patient lives through enhanced collaboration and a steadfast commitment to quality care.



ISHIC, as a key component of the hub, aims to accelerate the adoption of innovative healthcare solutions in clinics and hospitals throughout India, making healthcare more patient-centric, affordable, and accessible. By providing a platform for Indian and foreign innovators to work alongside leading doctors, the hub ensures that solutions are well suited to real-world medical settings, bridging the gap between scientific advancements and their practical implementation.



In collaboration with ISHIC, AstraZeneca serves as the knowledge partner and has initiated pilot projects in various states.

- **Qure.ai**, which utilises AI-powered chest X-Ray analysis for the detection of lung nodules (precursors of lung cancer).
- **Alveofit**, which offers a handheld digital spirometer for Pulmonary Function Tests (PFTs)—the primary diagnostic tests for pulmonary obstructive diseases.
- **Tricog**, an AI-powered ECG interpretation software that enables round-the-clock intervention by human experts. The Tricog tool provides rapid ECG reports within five minutes across India, validated by experts, aiming to reduce the critical golden hour in the event of a cardiac emergency.

These projects are focused on shaping early diagnosis in critical areas such as lung cancer, pulmonary obstructive diseases (COPD, asthma), and cardiovascular diseases.

Growth and Therapy Area Leadership

As the burden of disease grows and the population ages, we believe that science is key to helping unlock the answers to healthcare challenges.

The Approach



Harnessing the Company's cutting-edge scientific advancements to enhance the healthcare experience, making it more tailored, accurate, and easily accessible.



Actively collaborating with the entire healthcare ecosystem and forging visionary partnerships that foster positive transformations and yield favourable outcomes.



Delivering exceptional growth within the Company's therapy areas and regions, positioning ourselves as industry leaders.

CVRM

AstraZeneca is deeply engaged in unravelling the underlying causes of CVRM diseases. The Company identifies novel targets linked to disease biology, paving the way for the development of the next generation of therapeutics.

The global burden of CVRM diseases on individuals, economies, and healthcare systems is staggering. The increasing rates of obesity, coupled with an aging population, will significantly amplify the risk of CVRM diseases in the coming decade. Many of these conditions are currently underdiagnosed and undertreated. AstraZeneca aims to provide the right medicines and tailored solutions to specific patient populations, addressing the challenges across the entire CVRM spectrum.



Project Heart Beat

This initiative focuses on accurate and early diagnosis of severe chest pain patients at remote General Practitioner (GP) clinics through the use of Artificial Intelligence (AI)-enabled ECG machines. The goal is to provide appropriate care and ensure the timely transfer of critical Myocardial infarction (MI) patients to specialist Cardiac Hubs, thereby saving lives. AstraZeneca has established 25 Cardiac Hubs and connected 125 remote GP clinics. Till date, 49,087 severe chest pain patients have been screened, with 20,696 abnormal ECGs diagnosed and 3,280 critical MIs identified in under 4 minutes. These patients received timely medical care at GP clinics or the Cardiac Hubs as needed.

The project received recognition from the IHW Council for Digital Health award in 2022, AstraZeneca Global for its leading patient-centricity program, and was featured in the AZ Global Sustainability Report for providing equitable access to healthcare.



Project SEARCH

AstraZeneca collaborated with the Indian Society of Nephrology (ISN) to conduct chronic kidney disease screening for 'At-risk' patients with Type 2 diabetes mellitus (T2DM) and hypertension (HTN) to enable early identification and timely action. The screening program was conducted across India in collaboration with 1,500 physician clinics and 20 public-sector hospitals, reaching approximately 1,40,000 patients. Initial reports indicate that 30-35% of patients were identified with abnormal Urinary Albumin-to-Creatinine Ratio (UACR). The data is currently being reviewed for publication by the Indian Society of Nephrology.



Disease Awareness

AstraZeneca had dedicatedly laid emphasis on generating disease awareness among people. It leveraged the Company's digital and social media assets to educate the community at large about cardiovascular disease, diabetes, and their complications. The Company collaborated with the Research Society for the Study of Diabetes in India (RSSDI) and the ISN to co-create content and conduct LIVE expert programs. Some of AstraZeneca's key platforms have now matured and are well-recognised amongst HCPs and patients who seek authentic disease information. In 2022, the #BeyondSugar and #HeartMitra campaigns generated 600 patient education posts and conducted 90 live expert sessions with leading diabetologists, cardiologists, and nephrologists across the country. The content reached 36 million social media users and recorded 7.5 million video views.

49,087

Chest pain patients screened

20,696

Abnormal ECGs diagnosed

3,280

Critical MIs identified in under 4 minutes

1,40,000

Patients reached through Project SEARCH

~35%

Patients identified with UACR

600

Number of patient education posts

90

Live expert sessions



Growth and Therapy
Area Leadership

Oncology

AstraZeneca is committed to advancing the frontiers of scientific discovery to bring about remarkable transformation in the field of Oncology. The goal is to improve the lives of cancer patients by enabling access to novel treatment solutions. The strategy entails the introduction of new scientific platforms that strike cancer from multiple dimensions, involving the direct targeting of cancer cells and the activation of the immune system. AstraZeneca strives to achieve a deeper and more durable response by deploying both monotherapy and combination approaches, thus targeting various aspects of cancer, including genetic mutations, DNA damage response, epigenetics, and immune system activation.

The ambition is to follow the science to discover, develop, and deliver life-changing treatments and have a transformative impact on the lives of those living with cancer. Detecting and treating cancer at an early stage is crucial in improving five-year survival rate for people with largely prevalent cancers in India, such as lung, gastro-intestinal, and breast cancers, as the possibility for a potential cure is at its peak.

Towards the objective of transforming Cancer Care, AstraZeneca strives to build partnerships and collaborations with ecosystem players, harnessing their capabilities and expertise towards solving some of the structural challenges in improving patient outcomes. As part of the A.Catalyst network, constant evaluation of technology solutions, such as computational pathology, circulating tumor DNA (ctDNA) testing, digital health, and data science/AI is undertaken.

Lung Ambition Alliance

The Lung Ambition Alliance is a pioneering global initiative that seeks to revolutionise the landscape of lung cancer treatment by bringing together the resources and expertise of patient organisations, medical and scientific societies, and industry partners. The aim is to accelerate progress and achieve the ambitious goal of doubling the five-year survival rate for early-stage lung cancer patients worldwide. The collaborative approach, rooted in diversity and inclusivity, ensures the identification and addressing of the most pressing needs in the field, ultimately improving outcomes for those affected by this devastating disease.

In India, a start has been made with 18,000+ scans during the FY 2022-23, with a determination to accelerate the journey towards making a significant impact and taking the steps to achieve early detection through strategic tie-ups with hospital networks and the Government. With an aspiring plan to conduct a much higher number of scans in the forthcoming year, AstraZeneca is committed to creating a transformative change in the healthcare landscape of India. The unwavering dedication and persistent focus on achieving this goal will not only improve the health outcomes of people but also inspire a sense of hope and optimism in the fight against cancer.

HRD Testing for Ovarian Cancer

The transformation of the diagnostic landscape with Homologous Recombination Deficiency (HRD) testing for ovarian cancer has been a game-changer for precision medicine. By bringing together global and local expertise in diagnostics and promoting the science of HRD testing, AstraZeneca has been able to help reduce the cost burden on patients, cutting the cost of testing by more than 50%. In addition to transforming the diagnostics landscape by accelerating HRD testing adoption, AstraZeneca has also improved the overall treatment outcome, thereby affecting the survival rates positively. During FY 2022-23, the utilisation of HRD tests multiplied manifold, registering an increase of 483% over the previous year. The mission is to continue to develop innovative solutions that have a lasting impact on the healthcare industry and make a memorable difference in the lives of millions of people.



Pink Dot Program

As AstraZeneca strengthens its focus on breast cancer, the initiative of the Pink Dot Program is another testament manifesting the commitment to personalised care and emphasising the pursuit of saving lives and empowering breast cancer patients. Through gBRCA testing and imparting genetic counselling for early breast cancer, AstraZeneca identifies patients at higher risk. Additionally, the Company develops personalised risk-reducing strategies and targeted interventions to proactively prevent the onset of the disease.

Respiratory and Immunology

A renowned leader in respiratory care across inhaled and biologic medicines, AstraZeneca is dedicated to transforming care in respiratory and immune-mediated diseases. The Company aims to go beyond symptom control and achieve disease modification, remission, and, ultimately, a cure for millions of patients worldwide.


Addressing Asthma

In India, there is a significant burden of chronic respiratory illness, particularly asthma. With 34.3 million asthma patients, accounting for 13.09% of the global burden, the country faces a major challenge. Poor air quality due to pollution in major cities remains a significant cause of the high respiratory disease burden.

Severe asthma, which causes substantial morbidity and mortality, affects a large number of people in India. The diagnosis and treatment of severe asthma require a comprehensive and personalised approach. Specialised treatment centers, continued medical education, and research on disease prevalence are crucial needs. Severe asthma has evolved into a complex and heterogeneous disease with multiple underlying drivers. Despite advancements in understanding its pathophysiology and the availability of reliable diagnostic tools, severe asthma remains poorly managed in India.

Severe Asthma Clinics

AstraZeneca's contributions to helping asthma patients include the introduction of Symbicort, an inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination with an innovative delivery mechanism. Our Company's representatives provide support to patients using Symbicort to ensure optimal disease control through correct device usage.



▲ 17%
Market category growth
in FY 2022-23

▲ 483%
Increase in utilisation of HRD
tests for ovarian cancer

18,000+
Number of lung cancer scans
in FY 2022-23

For many years, Oral Corticosteroids (OCS) have been the standard treatment for severe asthma, but their long-term use is associated with multiple side effects and a burden on patients' quality of life. AstraZeneca advocates for evidence-based guidelines and the adoption of strategies to reduce OCS dependency.

The launch of Fasenra in India in April 2021 provided a better treatment option for severe eosinophilic asthma patients. Fasenra is an add-on maintenance therapy that targets eosinophils, a key cause of the eosinophilic subtype of asthma. Administered once every eight weeks through subcutaneous injection, Fasenra is not an inhaler or a steroid. Studies have shown that it can significantly reduce oral steroid intake, thereby reducing potential steroid-related side effects.

AstraZeneca's commercial and medical teams actively engage with leading pulmonologists to disseminate the robust clinical and real-world evidence of Fasenra across India. To standardise the management of severe asthma patients, the Company is establishing Severe Asthma Clinics. These clinics focus on four key pillars: Identifying the right patient profile for severe asthma, enhancing patient awareness through education, providing a dedicated curriculum for respiratory specialists, and developing an academy for asthma counsellors to assess patient care techniques, ensure medication adherence, and monitor asthma control.

People and Sustainability

AstraZeneca’s unwavering trust in the power of science continues to inspire sustainable growth and transformative breakthroughs in the future of healthcare, benefiting people, society, and the planet. The Company’s purpose and unwavering commitment to ethical conduct underpin its efforts to build healthier societies and foster partnerships aimed at tackling significant health challenges

The Approach

Sustainability is deeply ingrained in AstraZeneca’s approach, leveraging the power of science, innovation, and its global reach to create a healthy future for all stakeholders. The Company actively contributes to addressing pressing global challenges such as climate change, healthcare accessibility, and disease prevention. A science-led approach, coupled with a commitment to acting with integrity in accordance with its values, enables AstraZeneca to drive positive impact and transform the future of healthcare.

Three-pronged Sustainability Ambitions



Access to Healthcare

Increasing access to life-saving treatments, promoting prevention, and strengthening global healthcare resilience and sustainability



Environmental Protection

Accelerating the delivery of net-zero healthcare, proactively managing the Company’s environmental impact across all activities, and investing in nature and biodiversity



Ethics and Transparency

Ensuring ethical, open, and inclusive behaviour across all aspects of our operations

AstraZeneca's dedication to sustainability goes beyond the impact of its life-changing medicines, as it integrates sustainability principles across all aspects of its operations.

Access to Healthcare

AstraZeneca's initiatives are dedicated to increasing access to healthcare by implementing preventative cancer screenings in underserved communities and facilitating remote consultations with specialists, thereby addressing the healthcare needs of vulnerable populations.

Ganga Godavari Screening Program

The flagship initiative, the Ganga Godavari Screening Program, continues to prioritise the early detection of cancer in underserved communities, specifically focusing on women aged between 30 and 60 years. Now in its third year, the program has expanded its reach to multiple regions and established collaborations with the Indian Cancer Society (ICS) and CAPED India to amplify its impact.

Complementing the National Cancer Grid

AstraZeneca initiated a program to support the National Cancer Grid (NCG), an Indian government initiative aimed at improving standards of care for cancer patients. Through collaboration with Navya, remote consultations with cancer specialists at Tata Memorial Center and other NCG centers were facilitated. This program has greatly benefited 157 patients across India, particularly aiding low-income individuals in receiving high-quality care.

130

Cancer screening camps for women organised

8,500

Women benefited

1,100

Women were identified as at risk and referred for further medical treatment



Ganga Godavari Screening Program

People and Sustainability

Young Health Program

The Global Young Health Program, established in partnership with the John Hopkins School of Public Health and Plan International, focuses on enhancing health outcomes for vulnerable youth. In Delhi and Karnataka, the program has been implemented through peer educators who act as influential figures within their communities, spreading awareness about the harmful effects of behaviors such as tobacco and alcohol consumption, smoking, and unhealthy lifestyles. The initiative in Karnataka has six Health Information Centers (HICs) successfully operating in various communities. These centers empower young people, raise awareness among parents and teachers, strengthen health services, and advocate for institutional support and policy environments for non-communicable disease (NCD) prevention.

130,000

Number of people reached through campaigns and interventions in new territories

Community Engagement and Government Support

AstraZeneca strategically engages with local government bodies and health offices in Karnataka, including the Ministry of Health and Family Welfare (MoHFW) and the NCD Cell, as well as national health mission teams. This collaboration strengthens grassroots connections and enables the refinement of strategies for effective work in new communities.

Peer Educator Identification and Training

The program places significant importance on identifying and training peer educators for young people, who play a crucial role in spreading knowledge about NCD risk behaviors among their peers in schools and communities. These peer educators serve as agents of change, utilising various platforms such as observing important health days, the Nehru Yuva Kendra Sansthan (NYKS), the Rajiv Gandhi National Institute of Youth Development (RGNIYD), and collaboration with the Health Department to raise awareness among young people about NCD prevention.

To reinforce the program's message within the community, school teachers from government schools were sensitised and trained on the harms of alcohol and tobacco consumption, risky sexual behaviors, unhealthy diets, and physical inactivity. This enabled teachers to cascade the knowledge to young students in their schools.

Awareness Building for Health Promotion

Engaging the community in observing important health days became a continuous method of reiterating the message. The Young Health Program (YHP) team, along with peer educators, organised multiple mass events and campaigns on special health days to raise awareness among young people and community members. These events included medical sessions on NCDs and their risk factors, drawing competitions, video sessions, and health talks aimed at increasing awareness and addressing questions. In the previous year, over 6,000 young people participated in these events, virtually and physically, during the observance of about 12 health days.

Through interventions in new territories, the program reached approximately 1.3 lakh people, significantly raising awareness about NCDs, their causes, and their impacts. In line with the program's design, over 560 youth, 150 teachers, and 13 government facilitators were offered training on the subject.



AstraZeneca, in partnership with the Make-A-Wish Foundation, took the promise of care further by pledging to fulfil the wishes of around 550 critically ill children across the country. This initiative was aimed to enhance treatment adherence and advance the commitment to care. Conversations with healthcare professionals treating children have shown that granting a child's wish has a positive impact on their treatment journey. Granting wishes serves as a valuable complement to medical care, as it has been observed that patients feel better and are more likely to adhere to treatment protocols when their wishes are fulfilled. AstraZeneca India supported a series of 11 programs held across various cities in India, including Bengaluru, New Delhi, Mumbai, Kolkata, Vellore, Chennai, Hyderabad, and Ahmedabad, with the aim of connecting with as many children, between the ages of 3 to 18, and creating joyous memories.

Environment Protection

Acknowledging the intricate link between a thriving planet and the well-being of individuals, AstraZeneca adopts a science-based approach to proactively manage its environmental impact. The Company actively invests in biodiversity and nature conservation as part of its Ambition Zero Carbon ambition. Through the AZ Forest program, AstraZeneca collaborates with local governments and non-profit organisations worldwide to restore forests and promote biodiversity by planting trees. In India, the Company partnered with the SankalpTaru Foundation to plant and maintain geo-tagged trees, allowing for individual tracking and remote monitoring of their growth. These initiatives contribute to our efforts to achieve a healthier planet.



Young Health Program

 **People and Sustainability**

People

AstraZeneca is dedicated to the well-being and career development of its employees, providing tailored initiatives and fostering inclusivity. Through ongoing efforts, AstraZeneca has solidified its reputation as a preferred employer, exemplified by its Great Place to Work certification.

Focus Areas



Continuing to make AstraZeneca a Great Place to Work



Making it easier to work across therapy areas in India and deliver sustainable growth



Harnessing the power of science and innovation in ways that positively impact patients, healthcare systems, and the environment



Ensuring operating in the smartest way, increasing the speed of delivery of medicines to patients through the 'Future of Work' initiative

AstraZeneca is dedicated to cultivating an inclusive and fair environment in which every individual feels a sense of belonging. The Company recognises the value of its diverse talent and considers it a competitive advantage. A culture of continuous learning is nurtured, encouraging employees to enhance their skills and embrace the courage to challenge norms and explore new possibilities.

Efforts are made to streamline work processes, boost efficiency, and harness the power of digital technology to enhance the employee experience and improve patient outcomes. AstraZeneca envisions a future where affordable, sustainable, and innovative healthcare is accessible to all individuals, striving to make this vision a reality.

The Company empowers its employees through the implementation of a robust Code of Ethics. This code serves as a guiding framework, enabling individuals to make decisions that are aligned with the best interests of the Company and society as a whole.

Empowering People

- 1 Continued commitment to investing in employees, with a focus on attracting, retaining, and nurturing a skilled workforce
- 2 High scores consistently obtained in Pulse Surveys across various aspects, including Purpose and Values, engagement, health and well-being, sustainability, diversity and inclusion, organisational effectiveness, and talent and development

